Vanda Pharmaceuticals Inc. VNDA on Tuesday shared topline results from a pivotal Phase 3 trial evaluating HETLIOZ ...
Vanda Pharmaceuticals Inc. ( VNDA) announced positive topline results from its pivotal Phase 3 study of HETLIOZ (tasimelteon) in adults with Delayed Sleep-Wake Phase Disorder, a circadian rhythm ...
Vanda Pharmaceuticals Inc. ( VNDA) reported positive topline results from a Phase 3 study of HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). The study met its ...
Vanda Pharmaceuticals' (VNDA) phase 3 study of Hetlioz in adults with delayed sleep-wake phase disorder met its primary endpoint, shifting sleep onset 37 minutes earlier than plac ...
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder ...
Delayed sleep phase disorder (DSPD), more often known as delayed sleep phase syndrome and also as delayed sleep–wake phase disorder, is a chronic dysregulation of a person's circadian rhythm ...
In adolescents and young adults, delayed sleep-wake phase disorder (DSWPD) may be associated with attention-deficit/hyperactivity disorder (ADHD) and restless legs ...
Vanda said a late-stage study of Hetlioz (tasimelteon), already sold for two rare body-clock disorders, met its main goal in ...
Melatonin, an endogenously produced indoleamine, plays a central role in synchronising the sleep–wake cycle in children. Its secretion by the pineal gland under dim-light conditions facilitates the ...
Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ® treated participants shifted sleep at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results